

AREV LIFE SCIENCES GLOBAL CORP.  
PRESS RELEASE

**AREV Annual General Meeting Results**

VANCOUVER, BC / January 4, 2023 / AREV LIFE SCIENCES GLOBAL CORP. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation is pleased to announce the outcome of the votes at the annual meetings of the shareholders of AREV held on January 4, 2022 in Vancouver, British Columbia.

On January 4, 2023, AREV held its Annual General Meeting; the results follow:

Item 1: Number of Directors

The number of Directors was set to the election of six (6); this item was passed by ordinary resolution.

Item 2: Election of Directors

The six (6) nominees set forth in the November 21, 2022 management information circular of the Company (Mike Withrow, Denby Greenslade, Melvin Maxwell, Allan Echino, Brian Elliott and Kevin Phelps) were elected as Directors of the Company through adoption of an ordinary resolution.

Item 3: Appointment of Auditors

MNP LLP (formerly Harbourside CPA LLP) was appointed as the “Auditors of the Corporation” for the ensuing year, and the Directors were authorized to fix the auditors’ remuneration, all approved by the shareholders through act of an ordinary resolution.

Item 4: Approval of Incentive Stock Option Plan

The proposed Stock Option Plan, to which the Directors are now authorized to make modifications, in accordance with the Stock Option Plan and policies of the Canadian Securities Exchange, was passed by ordinary resolution.

For further information, contact Mike Withrow, [mike@AREVBrands.com](mailto:mike@AREVBrands.com) (778) 896-6536. For more information visit <https://www.arevlifesciences.com/>.

On behalf of the Board,

Mike Withrow  
CEO & Director

**About AREV Life Sciences Global Corp.**

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company’s business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage.

AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECANADA and The Biotechnology Innovation Organization (BIO).

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**



## FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com).